<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35580691</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-6017</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>14</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pharmaceutical sciences</Title>
          <ISOAbbreviation>J Pharm Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>An evolving role of aqueous piperazine to improve the solubility of non-steroidal anti-inflammatory drugs.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">S0022-3549(22)00199-X</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xphs.2022.05.009</ELocationID>
        <Abstract>
          <AbstractText>Piperazine (PIP) is a pharmaceutically acceptable molecule and a good co-conformer in crystallographic engineering. Most of the non-steroidal anti-inflammatory drugs (NSAIDs) have poor aqueous solubility, which hinders their clinical application. The reports show that the solubility of many insoluble drugs can be significantly improved through salt formation with the PIP. In this work, we obtained a series of NSAIDs-PIP salts, such as ibuprofen-piperazine (IBU-0.5PIP) salt, indomethacin-piperazine (IND-0.5PIP) salt, sulindac-piperazine (SUL-0.5PIP) salt, phenylbutazone-piperazine (PBZ-0.5PIP) salt, ketoprofen-piperazine (KPF-0.5PIP) salt and flurbiprofen-piperazine (FLB-0.5PIP) salt. The spatial structure, arrangement, interaction and associations were expatiated by single crystal X-ray diffraction. Powder X-ray diffraction, Fourier transform infrared, differential scanning calorimetry, and thermogravimetric analysis were used to characterize the novel salts. The six new salts had more than 10 folds of solubility and a faster dissolution rate improved corresponding to the bulk drugs in pure water, and the significant improvement of solubility is closely related to the structure of salts.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Zhengyu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Baoxi</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xing</LastName>
            <ForeName>Wenhui</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Hongmei</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xing</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gong</LastName>
            <ForeName>Ningbo</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. Electronic address: gnb@imm.ac.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Du</LastName>
            <ForeName>Guanhua</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing City Key Laboratory of Drug Target Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Pharm Sci</MedlineTA>
        <NlmUniqueID>2985195R</NlmUniqueID>
        <ISSNLinking>0022-3549</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Crystal structure</Keyword>
        <Keyword MajorTopicYN="N">NSAIDs</Keyword>
        <Keyword MajorTopicYN="N">Piperazine</Keyword>
        <Keyword MajorTopicYN="N">Salts formation</Keyword>
        <Keyword MajorTopicYN="N">Solubility</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare no competing financial interest</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>19</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35580691</ArticleId>
        <ArticleId IdType="doi">10.1016/j.xphs.2022.05.009</ArticleId>
        <ArticleId IdType="pii">S0022-3549(22)00199-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
